bioAffinity Technologies (BIAF) Receivables - Net (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Receivables - Net for 6 consecutive years, with $685235.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 28.9% year-over-year to $685235.0; the TTM figure through Mar 2026 stood at $685235.0 (down 28.9% YoY), while the FY2025 annual figure was $541962.0, down 52.43% from the prior year.
• Receivables - Net advanced to $685235.0 in Q1 2026 per BIAF's latest filing, from $541962.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $1.6 million in Q2 2024 and bottomed at $9930.0 in Q3 2022.
• Historically, Receivables - Net has averaged $685944.9 across 5 years, with a median of $685235.0 in 2026.
• Annual changes were most pronounced in 2023 — Receivables - Net jumped 11062.28% — and 2025, when it plunged 73.56%.
• bioAffinity Technologies' Receivables - Net stood at $10489.0 in 2022, then jumped by 7638.34% to $811674.0 in 2023, then soared by 40.35% to $1.1 million in 2024, then sank by 52.43% to $541962.0 in 2025, then advanced by 26.44% to $685235.0 in 2026.
• Business Quant data shows BIAF's Receivables - Net at $685235.0 in Q1 2026, $541962.0 in Q4 2025, and $448990.0 in Q3 2025.